Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort-Reference-Cited by-同舟云学术

Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort

Published:2011 Issue:6 Volume:13 Page:R211
ISSN:1478-6354
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Nikpour Mandana,Hissaria Pravin,Byron Jillian,Sahhar Joanne,Micallef Maree,Paspaliaris William,Roddy Janet,Nash Peter,Sturgess Alan,Proudman Susanna,Stevens Wendy

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference17 articles.

1. Epidemiology of systemic sclerosis

2. Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: Application to enzyme-linked immunosorbent assay

3. A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis

4. Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population

5. Anti-RNA Polymerase III Antibody Prevalence and Associated Clinical Manifestations in a Large Series of French Patients with Systemic Sclerosis: A Cross-sectional Study

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio and systemic sclerosis and its complications: a systematic review and meta-analysis;Frontiers in Immunology;2024-05-10

2. The association of vasoactive-inotropic score and surgical patients’ outcomes: a systematic review and meta-analysis;Systematic Reviews;2024-01-06

3. The Clinical Aspects of Autoantibodies;Scleroderma;2024

4. Cancer in Systemic Sclerosis;Scleroderma;2024

5. Systemic sclerosis (scleroderma);The Rose and Mackay Textbook of Autoimmune Diseases;2024